GlassScriptPhysician profile
Susan George
NPI 1760176515
$4,319.42
in general payments reported to CMS, 2019-2025
20 companies · $2,945 in 2025
The $2,945 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,374 · 2025: $2,945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,319.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $498.13 | 2024-2025 | Qelbree |
| Alkermes, INC. | $471.21 | 2024-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $402.72 | 2024-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $349.24 | 2024-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $346.49 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $299.38 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $279.27 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $267.62 | 2024-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $233.73 | 2025 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $227.47 | 2024-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Abbvie INC. | $189.48 | 2025 | |
| Almatica Pharma LLC | $156.31 | 2024-2025 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $146.08 | 2025 | Trintellix |
| Lundbeck LLC | $145.81 | 2024-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $108.02 | 2024-2025 | Cobenfy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $60.51 | 2025 | Dyanavel Xr, Quillichew Er |
| Ironshore Pharmaceuticals INC. | $59.36 | 2024 | |
| Noven Therapeutics, LLC | $42.96 | 2024-2025 | Xelstrym |
| Tempus Ai, INC | $19.36 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $16.27 | 2025 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.